Imunon (IMNN) Projected to Post Earnings on Thursday

Imunon (NASDAQ:IMNN – Get Free Report) is projected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Imunon to post earnings of ($0.61) per share for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 11:00 AM ET.

Imunon (NASDAQ:IMNN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33. On average, analysts expect Imunon to post ($2.37) EPS for the current fiscal year and ($2.03) EPS for the next fiscal year.

Imunon Price Performance

Shares of Imunon stock opened at $0.77 on Wednesday. Imunon has a 12 month low of $0.77 and a 12 month high of $4.38. The stock has a 50 day moving average of $1.21 and a 200 day moving average of $2.15. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.82 and a quick ratio of 1.82.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Get Our Latest Research Report on Imunon

Imunon Company Profile

(Get Free Report)

Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells. Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.

Read More

Earnings History for Imunon (NASDAQ:IMNN)

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.